GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eidos Therapeutics Inc (NAS:EIDX) » Definitions » Preferred Stock

Eidos Therapeutics (Eidos Therapeutics) Preferred Stock : $0.00 Mil (As of Sep. 2020)


View and export this data going back to 2018. Start your Free Trial

What is Eidos Therapeutics Preferred Stock?

Preferred stock is a special equity security that has properties of both equity and debt. Eidos Therapeutics's preferred stock for the quarter that ended in Sep. 2020 was $0.00 Mil.

The market value of preferred stock needs to be added to the market value of common stocks in the calculation of Enterprise Value. Eidos Therapeutics's Enterprise Value for the quarter that ended in Sep. 2020 was $1,823.60 Mil.

In the calculation of book value, the par value of preferred stocks needs to subtracted from total equity. Eidos Therapeutics's Book Value per Share for the quarter that ended in Sep. 2020 was $3.18.

Dividends paid to preferred stocks need to be subtracted from net income in the calculation of Earnings per Share (Diluted). Eidos Therapeutics's Earnings per Share (Diluted) for the three months ended in Sep. 2020 was $-0.79.


Eidos Therapeutics Preferred Stock Historical Data

The historical data trend for Eidos Therapeutics's Preferred Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eidos Therapeutics Preferred Stock Chart

Eidos Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19
Preferred Stock
- - - -

Eidos Therapeutics Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20
Preferred Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Eidos Therapeutics Preferred Stock Calculation

Preferred Stock is a special equity security that has properties of both equity and debt. It is generally considered a hybrid instrument. Preferred stock is senior to common stock, but is subordinate to bonds in terms of claim or rights to their share of the assets of the company.

Preferred stock has priority over common stock in the payment of dividends and any payments received when a company liquidates.

Preferred stock comes in many forms. It can be:


Convertible or Non-Convertible
Cumulative or Non-Cumulative
Voting or Non-Voting
Callable or Non-Callable
Maturity Date or No Maturity Date

A preferred stock without a maturity date is called a perpetual preferred stock. These are relatively rare. A good example of perpetual preferred stock is the many series of Public Storage (PSA) preferred shares that trade on the New York Stock Exchange.

Before investing in preferred stock, it is important to know which of the above groups the stock belongs to. Is it convertible or non-convertible? Are dividends cumulative or non-cumulative?

It is also critical that an investor knows what bonds the company has in front of the preferred stock. Bondholders get paid first. So the decision to buy a preferred stock can be similar to the decision to buy a bond. But, remember, the preferred stock of a company with bonds is junior to those bonds.

Unless a preferred stock is convertible, the upside in a preferred stock investment is more limited than in a common stock investment. If a company doubles its earnings, it is usually under no more obligation to double the dividends paid to preferred shareholders than it is to double the interest paid to its bankers and bondholders.So preferred stock is very different from common stock.


Eidos Therapeutics  (NAS:EIDX) Preferred Stock Explanation

When a company needs capital but does not wish to issue debt, they may sell preferred stocks to investors.

For instance, during the financial crisis of 2008, Goldman Sachs (GS) issued a combination of preferred stock and common stock options for $5 billion of capital to Warren Buffett’s Berkshire Hathaway (BRK.A)(BRK.B). In this deal, Berkshire Hathaway paid $5 billion for 10% cumulative perpetual preferred stock and warrants to buy 43.5 million shares of Goldman Sachs at $115 a share. Goldman Sachs bought back the preferred in 2010. Guess how much money Warren Buffett made in this deal in two years? Read How Much Did Warren Buffett’s Berkshire Hathaway (BRK.B) Make on Its Goldman Sachs (GS) Preferred Stock?

1. The market value of Preferred Stocks needs to be added to the market value of common stocks in the calculation of enterprise value.

Eidos Therapeutics's Enterprise Value for the quarter that ended in Sep. 2020 is calculated as

2. In the calculation of Book Value, the par value of Preferred Stocks needs to subtracted from total equity.

Eidos Therapeutics's Book Value per Share for the quarter that ended in Sep. 2020 is calculated as

3. Dividends paid to Preferred Stocks need to be subtracted from net income in the calculation of earnings per share.

Eidos Therapeutics's Earnings per Share (Diluted) (EPS) for the three months ended in Sep. 2020 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eidos Therapeutics Preferred Stock Related Terms

Thank you for viewing the detailed overview of Eidos Therapeutics's Preferred Stock provided by GuruFocus.com. Please click on the following links to see related term pages.


Eidos Therapeutics (Eidos Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
101 Montgomery Street, Suite 2000, San Francisco, CA, USA, 94104
Eidos Therapeutics Inc is a clinical stage biopharmaceutical company focused on addressing the large and growing unmet need in diseases caused by transthyretin, or TTR, amyloidosis, or ATTR. TTR is a protein that occurs naturally in the form of a tetramer and performs multiple beneficial roles, including the transport of essential hormones and vitamins. The company's product candidate, AG10, is an orally-administered small molecule designed to potently stabilize tetrameric TTR.
Executives
Uma Sinha director, officer: Chief Scientific Officer C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Franco Valle officer: Senior Vice President, Finance 999 SKYWAY ROAD, SUITE 150, SAN CARLOS CA 94070
Cameron Turtle officer: Chief Business Officer C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94104
Jonathan C Fox officer: See Remarks C/O MYOKARDIA, INC., 333 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Suzanne Sawochka Hooper director C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2
Douglas Rohlen director 3600 HOLLY LANE NORTH, SUITE 40 PLYMOUTH MN 55447
Eric Aguiar director 888 7TH AVENUE, 12TH FLOOR, NEW YORK NY 10106
Rajeev M. Shah director 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Ali J. Satvat director, 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO., 2800 SAND HILL ROAD, SUITE 200, MENLO PARK CA 94025
William Lis director PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Christine Siu officer: CFO and Secretary C/O EIDOS THERAPEUTICS, INC., 101 MONTGOMERY STREET, SUITE 2550, SAN FRANCISCO CA 94101
Bridgebio Pharma, Inc. 10 percent owner 421 KIPLING STREET PALO ALTO CA 94301
Neil Kumar director, 10 percent owner, officer: Chief Executive Officer C/O BRIDGEBIO PHARMA, INC., 3160 PORTER DR, STE 250, PALO ALTO CA 94304
Hoyoung Huh director C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Peter Kolchinsky 10 percent owner 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116

Eidos Therapeutics (Eidos Therapeutics) Headlines

From GuruFocus